Bio-Gene Technology Limited (ASX:BGT)
Australia · Delayed Price · Currency is AUD 0.0350
+0.0040 (12.90%)
Jan 30, 2026, 3:19 PM AEST
Bio-Gene Technology Market Cap
Bio-Gene Technology has a market cap or net worth of 9.46 million as of January 30, 2026. Its market cap has increased by 4.37% in one year.
Market Cap
9.46M
Enterprise Value
8.32M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
0.04
Market Cap Chart
Since November 29, 2017, Bio-Gene Technology's market cap has decreased from 20.89M to 9.46M, a decrease of -54.73%. That is a compound annual growth rate of -9.24%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 29, 2026 | 9.46M | 34.78% |
| Dec 29, 2025 | 7.02M | -18.97% |
| Dec 30, 2024 | 8.66M | -28.33% |
| Dec 29, 2023 | 12.08M | -32.09% |
| Dec 29, 2022 | 17.79M | -48.81% |
| Dec 31, 2021 | 34.76M | 61.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Immuron | 12.37M |
| AdAlta | 11.48M |
| Chimeric Therapeutics | 11.05M |
| Patrys | 10.22M |
| Invex Therapeutics | 8.64M |
| Zelira Therapeutics | 8.63M |
| Biotron | 8.43M |
| Vectus Biosystems | 6.95M |